N-Linked glycans on influenza A H3N2 hemagglutinin constrain binding of host antibodies, but shielding is limited

Glycobiology

Volumn 25, Issue 1, 2015, Pages 124-132

  Pentiah, Kevin ^a   Lees, William D ^a   Moss, David S ^a   Shepherd, Adrian J ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

bioinformatics; hemagglutinin; influenza A; N glycans

Indexed keywords

EPITOPE; GLYCAN DERIVATIVE; INFLUENZA VIRUS HEMAGGLUTININ; POLYSACCHARIDE; PROTEIN BINDING; VIRUS ANTIBODY;

ANTIGEN BINDING; ARTICLE; BINDING SITE; GLYCOSYLATION; HERD IMMUNITY; HOST; INFLUENZA A VIRUS (H3N2); MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; AMINO ACID SUBSTITUTION; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; GENETICS; HUMAN; INFLUENZA VIRUS A H3N2; MOLECULAR GENETICS; MUTATION; PROTEIN MOTIF;

AMINO ACID MOTIFS; AMINO ACID SUBSTITUTION; ANTIBODIES, VIRAL; BINDING SITES; CARBOHYDRATE CONFORMATION; GLYCOSYLATION; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; POLYSACCHARIDES; PROTEIN BINDING;

EID: 84924985609     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwu097     Document Type: Article

References (45)

1. Abe Y, Takashita E, Sugawara K, Matsuzaki Y, Muraki Y, Hongo S. 2004. Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin. J Virol. 78:9605-9611.
2. Aebi M, Bernasconi R, Clerc S, Molinari M. 2010. N-Glycan structures: Recognition and processing in the ER. Trends Biochem Sci. 35:74-82.
3. Barbey-Martin C, Gigant B, Bizebard T, Calder LJ, Wharton SA, Skehel JJ, Knossow M. 2002. An antibody that prevents the hemagglutinin low pH fusogenic transition. Virology. 294:70-74.
4. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. 2000. The Protein Data Bank. Nucleic Acids Res. 28:235-242.
5. Blackburne BP, Hay AJ, Goldstein RA. 2008. Changing selective pressure during antigenic changes in human influenza H3. PLoS Pathog. 4:e1000058.
6. Bush RM, Fitch WM, Bender CA, Cox NJ. 1999. Positive selection on the H3 hemagglutinin gene of human influenza virus A. Mol Biol Evol. 16:1457-1465.
7. Chen J-R, Yu Y-H, Tseng Y-C, Chiang W-L, Chiang M-F, Ko Y-A, Chiu Y-K, Ma H-H, Wu C-Y, Jan J-T, et al. 2014. Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections. Proc Natl Acad Sci USA. 111:2476-2481.
8. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, et al. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 333:850-856.
9. Daniels R, Kurowski B, Johnson AE, Hebert DN. 2003. N-Linked glycans direct the cotranslational folding pathway of influenza hemagglutinin. Mol Cell. 11:79-90.
10. Das SR, Hensley SE, David A, Schmidt L, Gibbs JS, Puigbò P, Ince WL, Bennink JR, Yewdell JW. 2011. Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategy. Proc Natl Acad Sci USA. 108:E1417-E1422.
11. Das SR, Puigbò P, Hensley SE, Hurt DE, Bennink JR, Yewdell JW. 2010. Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain. PLoS Pathog. 6:e1001211.
12. Edgar RC. 2004. MUSCLE: A multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics. 5:113.
13. Gallagher P, Henneberry J, Wilson I, Sambrook J, Gething MJ. 1988. Addition of carbohydrate side chains at novel sites on influenza virus hemagglutinin can modulate the folding, transport, and activity of the molecule. J Cell Biol. 107:2059-2073.
14. Iba Y, Fujii Y, Ohshima N, Sumida T, Kubota-Koketsu R, Ikeda M, Wakiyama M, Shirouzu M, Okada J, Okuno Y, et al. 2014. Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses. J Virol. 88:7130-7144.
15. Kobayashi Y, Suzuki Y. 2012. Evidence for N-glycan shielding of antigenic sites during evolution of human influenza A virus hemagglutinin. J Virol. 86:3446-3451.
16. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Briney BS, Smith SA, Basler CF, Crowe JE. 2011. Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence. J Immunol. 187:3704-3711.
17. Lees WD, Moss DS, Shepherd AJ. 2010. A computational analysis of the antigenic properties of haemagglutinin in influenza A H3N2. Bioinforma Oxf Engl. 26:1403-1408.
18. Lees WD, Moss DS, Shepherd AJ. 2011. Analysis of antigenically important residues in human influenza A virus in terms of B-cell epitopes. J Virol. 85:8548-8555.
19. Lees WD, Moss DS, Shepherd AJ. 2014. Evolution in the influenza A H3 stalk-A challenge for broad-spectrum vaccines? J Gen Virol. 95:317-324.
20. Lin YP, Xiong X, Wharton SA, Martin SR, Coombs PJ, Vachieri SG, Christodoulou E, Walker PA, Liu J, Skehel JJ, et al. 2012. Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc Natl Acad Sci USA. 109:21474-9.
21. Mir-Shekari SY, Ashford DA, Harvey DJ, Dwek RA, Schulze IT. 1997. The glycosylation of the influenza Avirus hemagglutinin by mammalian cells. A site-specific study. J Biol Chem. 272:4027-4036.
22. Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF, Halper-Stromberg A, Gnanapragasam PNP, Spencer DIR, Seaman MS, et al. 2012. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci USA. 109:E3268-E3277.
23. Munk K, Pritzer E, Kretzschmar E, Gutte B, Garten W, Klenk HD. 1992. Carbohydrate masking of an antigenic epitope of influenza virus haemagglutinin independent of oligosaccharide size. Glycobiology. 2:233-240.
24. Ohuchi M, Ohuchi R, Feldmann A, Klenk HD. 1997. Regulation of receptor binding affinity of influenza virus hemagglutinin by its carbohydrate moiety. J Virol. 71:8377-8384.
25. Ohuchi R, Ohuchi M, GartenW, Klenk HD. 1997. Oligosaccharides in the stem region maintain the influenza virus hemagglutinin in the metastable form required for fusion activity. J Virol. 71:3719-3725.
26. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang P-S, Wang S-K, Stanfield RL, Julien J-P, Ramos A, Crispin M, et al. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science. 334:1097-1103.
27. Schulze IT. 1997. Effects of glycosylation on the properties and functions of influenza virus hemagglutinin. J Infect Dis. 176(Suppl.):S24-S28.
28. Shih AC-C, Hsiao T-C, Ho M-S, Li W-H. 2007. Simultaneous amino acid substitutions at antigenic sites drive influenza A hemagglutinin evolution. Proc Natl Acad Sci USA. 104:6283-6288.
29. Skehel JJ, Stevens DJ, Daniels RS, Douglas AR, Knossow M, Wilson IA, Wiley DC. 1984. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci USA. 81:1779-1783.
30. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus ADME, Fouchier RAM. 2004. Mapping the antigenic and genetic evolution of influenza virus. Science. 305:371-376.
31. Tate MD, Job ER, Deng Y-M, Gunalan V, Maurer-Stroh S, Reading PC. 2014. Playing hide and seek: How glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses. 6:1294-1316.
32. Toth AM, Kuo C-W, Khoo K-H, Jarvis DL. 2014. A new insect cell glycoengineering approach provides baculovirus-inducible glycogene expression and increases human-type glycosylation efficiency. J Biotechnol. 182-183:19-29.
33. Venkatramani L, Bochkareva E, Lee JT, Gulati U, Graeme Laver W, Bochkarev A, Air GM. 2006. An epidemiologically significant epitope of a 1998 human influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complex. J Mol Biol. 356:651-663.
34. Verhoeyen M, Fang R, Jou WM, Devos R, Huylebroeck D, Saman E, Fiers W. 1980. Antigenic drift between the haemagglutinin of the Hong Kong influenza strains A/Aichi/2/68 and A/Victoria/3/75. Nature. 286:771-776.
35. Vigerust DJ, Shepherd VL. 2007. Virus glycosylation: Role in virulence and immune interactions. Trends Microbiol. 15:211-218.
36. Vigerust DJ, Ulett KB, Boyd KL, Madsen J, Hawgood S, McCullers JA. 2007. N-Linked glycosylation attenuates H3N2 influenza viruses. J Virol. 81:8593-8600.
37. Wang C-C, Chen J-R, Tseng Y-C, Hsu C-H, Hung Y-F, Chen S-W, Chen C-M, Khoo K-H, Cheng T-J, Cheng Y-SE, et al. 2009. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc Natl Acad Sci USA. 106:18137-18142.
38. Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, Palese P. 2010. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 6:e1000796.
39. Ward CW, Dopheide TA. 1981. Amino acid sequence and oligosaccharide distribution of the haemagglutinin from an early Hong Kong influenza virus variant A/Aichi/2/68 (X-31). Biochem J. 193:953-962.
40. Ward CW, Gleeson PA, Dopheide TA. 1980. Carbohydrate composition of the oligosaccharide units of the haemagglutinin from the Hong Kong influenza virus A/Memphis/102/72. Biochem J. 189:649-652.
41. Wiley DC, Skehel JJ. 1987. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem. 56:365-394.
42. Wilson IA, Skehel JJ, Wiley DC. 1981. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature. 289: 366-373.
43. World Health Organization. 2009. Influenza WHO Fact Sheet no. 211. World Health Organization. Available from: http://www. who. int/mediacentre/fact sheets/fs211/en/
44. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE, Wilson IA. 2010. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. 328:357-360.
45. Zhang M, Gaschen B, Blay W, Foley B, Haigwood N, Kuiken C, Korber B. 2004. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCVenvelopes and influenza hemagglutinin. Glycobiology. 14:1229-1246.